CareFirst Family of health care plans

CVS caremark™

Kineret

Prior Authorization Request

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____
Request Initiated For: _____

1. Has the patient been diagnosed with any of the following?
   - ❑ Rheumatoid arthritis (RA), moderately to severely active
   - ❑ Adult-onset Still's disease
   - ❑ Systemic juvenile idiopathic arthritis (sJIA), active
   - ❑ Cryopyrin-Associated Periodic Syndrome (CAPS), including Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
   - ❑ Recurrent pericarditis
   - ❑ Multicentric Castleman's disease
   - ❑ Hyperimmunoglobulin D Syndrome [Mevalonate Kinase Deficiency (MKD)]
   - ❑ Polyarticular juvenile idiopathic arthritis
   - ❑ Other _____

2. What is the ICD-10 code? _____
   No further questions if diagnosis is CAPS (NOMID), multicentric Castleman's disease or Hyperimmunoglobin D Syndrome.

Section A: Preferred Product

3. These are the preferred products for which coverage is provided for treatment of the following condition: Rheumatoid arthritis: **Enbrel, Humira, Kevzara, Orencia (subcutaneous)/Orencia ClickJect**
   Can the patient's treatment be switched to a preferred product?
   - ❑ Yes - Please specify: _____ ***If Yes, please call 1-866-814-5506 to have the updated form faxed to your office OR you may complete the PA electronically (ePA). You may sign up online via CoverMyMeds at: www.covermymeds.com/epa/caremark/ or call 1-866-452-5017.***
   - ❑ No
   - ❑ Not applicable - Requested for condition not listed above, *skip to diagnosis section.*

4. Is this request for continuation of therapy with the requested product? ❑ Yes ❑ No *If No, skip to #6*

5. Is the patient currently receiving the requested product through samples or a manufacturer's patient assistance program? If unknown, answer Yes. ❑ Yes ❑ No *If No, skip to diagnosis section.*

6. Has the patient had a documented inadequate response or intolerable adverse event with any of the following preferred products? Please indicate ALL that apply. ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***

❑ Enbrel:	❑ Inadequate response	❑ Intolerable adverse event
❑ Humira:	❑ Inadequate response	❑ Intolerable adverse event
❑ Kevzara:	❑ Inadequate response	❑ Intolerable adverse event
❑ Orencia (SC/ClickJect):	❑ Inadequate response	❑ Intolerable adverse event

❑ No - none of the above

7. Does the patient have one of the following documented clinical reasons to avoid Enbrel and Humira? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***

❑ Yes - History of demyelinating disorder ❑ Yes - Autoantibody formation/lupus-like syndrome
❑ Yes - History of congestive heart failure ❑ Yes - Risk of lymphoma
❑ Yes - History of hepatitis B virus infection ❑ No - none of the above

Complete the following section based on the patient's diagnosis, if applicable.

Section B: Adult-Onset Still's Disease

8. How long has the patient been receiving the requested medication? _____months ❑ Not started, *skip to #10*

9. If patient has received at least 3 months, has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms? ❑ Yes ❑ No *No further questions*

10. Has the patient experienced an inadequate response after at least 3 months of treatment OR intolerance to methotrexate? ❑ Yes ❑ No

11. Does the patient have a febrile disease? ❑ Yes ❑ No

12. Does the patient have a contraindication to methotrexate? ❑ Yes ❑ No

Section C: Recurrent Pericarditis

13. Has the patient failed a first-line therapy agent for the treatment of recurrent pericarditis (i.e., colchicine)? ❑ Yes ❑ No

Section D: Rheumatoid Arthritis

14. How long has the patient been receiving the requested medication? _____months ❑ Not started, *skip to #16*

15. If patient has received at least 3 months, has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms? ❑ Yes ❑ No *No further questions*

16. Has the patient experienced an inadequate response after at least 3 months of treatment OR intolerance to a biologic DMARD or targeted synthetic DMARD (e.g., Xeljanz)? ❑ Yes ❑ No

Section E: Systemic Juvenile Idiopathic Arthritis

17. How long has the patient been receiving the requested medication? _____months ❑ Not started, *skip to #19*

18. If patient has received at least 3 months, has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms? ❑ Yes ❑ No *No further questions*

19. Has the patient received Actemra or Ilaris in a paid claim through a pharmacy or medical benefit in the previous 120 days? ❑ Yes ❑ No

20. Has the patient experienced an inadequate response to treatment with corticosteroids (e.g., prednisone, methylprednisolone), methotrexate, or leflunomide? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**